Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler® in adolescents and adults with asthma

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 32-39

  Morice, Alyn H ^a   Hochmuth, Luděk ^b   Ekelund, Jan ^c   Thorén, Anders ^c   Puterman, Allan S ^d  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Fakultna nemocnica s poliklinikou FD Roosevelta Banska Bystrica   (Slovakia)

^c ASTRAZENECA R AND D   (Sweden)

^d Kingsbury Hospital   (South Africa)

Author keywords

Asthma; Budesonide formoterol; Dry powder inhaler; Pressurized metered dose inhaler; Safety

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRICANYL TURBUHALER; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; SYMBICORT RAPIHALER; TERBUTALINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HOARSENESS; HUMAN; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SINUSITIS; TACHYCARDIA; THRUSH; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; RESPIRATORY FUNCTION TESTS;

EID: 38049125953     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.10.006     Document Type: Article

References (42)

1. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. A national clinical guideline. Revised edition, April 2004. Available at 〈www.brit-thoracic.org.uk/c2/uploads/asthmafull.pdf〉 (accessed on 6 September 2005).
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA Workshop Report, Bethesda, MD: National Institutes for Health. NIH Publication No. 02-3659, 1995 (updated 2004).
3. Buhl R., Creemers J.P., Vondra V., Martelli N.A., Naya I.P., and Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97 (2003) 323-330
4. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
5. Pauwels R.A., Lofdahl C.-G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1411
6. Tal A., Simon G., Vermeulen J.H., et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34 (2002) 342-350
7. Zetterström O., Buhl R., Mellem H., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
8. Cochrane G.M., Horne R., and Chanez P. Compliance in asthma. Respir Med 93 (1999) 763-769
9. Lalloo U.G., Malolepszy J., Kozma D., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 123 (2003) 1480-1487
10. Rosenhall L., Heinig J.H., Lindqvist A., Leegaard J., Ståhl E., and Bergqvist P.B. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 56 (2002) 427-433
11. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., and Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003) 912-919
12. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
13. Bateman E.D., Bantje T.A., Joao Gomes M., et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2 (2003) 275-281
14. Aalbers R., Backer V., Kava T.T., et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 20 (2004) 225-240
15. FitzGerald J.M., Sears M.R., Boulet L.P., et al., for the Canadian Investigators. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 10 (2003) 427-434
16. Pohl W.R., Vetter N., Zwick H., and Hrubos W. Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. Respir Med 100 (2005) 551-560
17. Ställberg B., Olsson P., Jorgensen L.A., Lindarck N., and Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 57 (2003) 656-661
18. Balanag V.M., Yunus F., Yang P.C., and Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 19 (2006) 139-147
19. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
20. Rabe K.F., Pizzichini E., Ställberg B., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild to moderate asthma: a randomized, double-blind trial. Chest 129 (2006) 246-256
21. Scicchitano R., Aalbers R., Ukena D., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 (2004) 1403-1418
22. Vogelmeier C., D'Urzo A., Pauwels R., et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 26 (2005) 819-828
23. Crompton G.K. How to achieve good compliance with inhaled asthma therapy. Respir Med 98 Suppl B (2004) S35-S40
24. Barry P.W., and O'Callaghan C. The influence of inhaler selection on efficacy of asthma therapies. Adv Drug Deliv Rev 55 (2003) 879-923
25. Dolovich M.B., Ahrens R.C., Hess D.R., et al., for the American College of Chest Physicians and American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 127 (2005) 335-371
26. ® in adolescents and adults with asthma. J Allergy Clin Immunol 115 Suppl (2005) S2
27. ® in children with asthma. J Allergy Clin Immunol 115 Suppl (2005) S209
28. Rosenhall L., Elvstrand A., Tilling B., et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 97 (2003) 702-708
29. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136 (1987) 225-244
30. Hsu F.-F., Wang L., and Bier D.M. Determination of cortisol in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. Anal Biochem 216 (1994) 401-405
31. Quanjer Ph.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.-C. Lung volumes and forced ventilatory flows. Report working party: standardization of lung function tests. European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 6 Suppl 16 (1993) 5-40
32. European Agency for the Evaluation of Medicinal Products. Note for guidance on population exposure: the extent of population exposure to assess clinical safety. CPMP/ICH/375/95;1995. Available at 〈www.emea.eu.int/pdfs/human/ich/037595en.pdf〉 (accessed on 14 September 2005).
33. Rau J.L. The inhalation of drugs: advantages and problems. Respir Care 50 (2005) 367-382
34. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 104 (1999) S250-S252
35. Gabrio B.J., Stein S.W., and Velasquez D.J. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 186 (1999) 3-12
36. Chopra N., Williams M., Rimmer M., Kahl L., and Jenkins M. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Respir Med 99 Suppl A (2005) S1-S10 (Epub; Jan 26 2005:S1-S10)
37. Pearlman D.S., Peden D., Condemi J.J., et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 41 (2004) 797-806
38. Vastagh E., Kuna P., Calistruc P., and Bogdan M.A. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC. Respir Med 97 Suppl D (2003) S20-S28 S20-S28
39. McIntyre H.D., Mitchell C.A., Bowler S.D., Armstrong J.G., Wooler J.A., and Cowley D.M. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax 50 (1995) 1280-1284
40. Ankerst J., Persson G., and Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 16 (2003) 147-151
41. Bateman E.D., Silins V., and Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 95 (2001) 136-146
42. Brocklebank D., Wright J., and Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Br Med J 323 (2001) 896-900